ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

acalabrutinib

Also written as “Acalabrutinib”, “ACP-196” and “Acalabrutinib (ACP-196)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Lymphoma, Large B-Cell, Diffuse · COVID-19 · Hepatic Insufficiency, led by 4 companies.

Drug pageAcalabrutinib: every studyAll 123 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 11, 202155 company-led studies, 22 open or runningNext primary completion: Feb 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only5220 open or runningphase 4since Jun 11, 2021Jan 6, 2014Feb 15, 2027phase 3 · NCT02972840
AbbVie11 open or runningphase 3since May 20, 2024May 20, 2024Mar 2028phase 3 · NCT06428019
Ascentage Pharma Group Internationalits history only11 open or runningphase 3since Mar 13, 2024Mar 13, 2024Aug 2027phase 3 · NCT06319456
Ipsenits history only10 open or runningphase 2since Dec 29, 2021Dec 29, 2021none ahead

Also a collaborator on its studies: Apices Soluciones S.L., Hoffmann-La Roche, Fortrea, eResearch Technology, CISCRP, Parexel, Merck and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named acalabrutinibINNProposed as its International Nonproprietary Name in WHO's List 113 · before, ACP-196
  2. May 20, 2024First study: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT06428019 · 170 planned · United States, Australia, France and more

Ahead

  1. Mar 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06428019

TargetBeta

BTK →read by rule
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

The one study AbbVie leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3RecruitingMar 2028170

How it is read

Names in the registry

  • “Acalabrutinib”, 28 entries
  • “acalabrutinib”, 7 entries
  • “ACP-196”, 7 entries
  • “Acalabrutinib (ACP-196)”, 3 entries
  • “ACP-196 (acalabrutinib)”, 2 entries

Codes read as this program: ACP196.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.